Company Encyclopedia
View More
name
Treace Medical Concepts
TMCI.US
Treace Medical Concepts, Inc., a medical technology company, designs, manufactures, and markets medical devices in the United States. The company offers Lapiplasty 3D bunion correction system that combines instruments, implants, and surgical methods designed to correct three planes of the bunion deformity and secure the unstable joint, addressing the root cause of the bunion. It also provides Lapiplasty mini-incision system designed to allow the Lapiplasty procedure to be performed through a 3.5cm incision. In addition, the company offers Adductoplasty system designed for reproducible correction of metatarsus adductus deformities and osteoarthritis of the midfoot.
1.400 T
TMCI.USMarket value -Rank by Market Cap -/-

Financial Score

22/11/2025 Update
C
Health Care EquipmentIndustry
Industry Ranking78/170
Industry medianC
Industry averageC
Score Analysis
Peer Comparison
  • Criteria
    Rating
  • Profit ScoreD
    • ROE-51.63%E
    • Profit Margin-22.89%E
    • Gross Margin79.07%A
  • Growth ScoreC
    • Revenue YoY7.90%B
    • Net Profit YoY18.55%B
    • Total Assets YoY-7.67%D
    • Net Assets YoY-14.98%E
  • Cash ScoreC
    • Cash Flow Margin-436.81%E
    • OCF YoY7.90%B
  • Operating ScoreA
    • Turnover1.07A
  • Debt ScoreC
    • Gearing Ratio54.63%C

Valuation analysis

portai
P/E
1Y
3Y
5Y
10Y
P/E
-
Industry Ranking
-/-
  • P/E
  • Price
  • High
  • Median
  • Low
P/B
1Y
3Y
5Y
10Y
P/B
-
Industry Ranking
-/-
  • P/B
  • Price
  • High
  • Median
  • Low
P/S
1Y
3Y
5Y
10Y
P/S
-
Industry Ranking
-/-
  • P/S
  • Price
  • High
  • Median
  • Low
Dividend Yield
1Y
3Y
5Y
10Y
Dividend Yield
-
Industry Ranking
-/-
  • Dividend Yield
  • Price
  • High
  • Median
  • Low

Institutional View & Shareholder

Analyst Ratings

Rating
Percentage
    • Price
      --
    • Highest
      --
    • Lowest
      --
    News
    View More

    Treace Medical Concepts (TMCI) Receives a Hold from Truist Financial

    Truist Financial analyst Richard Newitter has reiterated a Hold rating on Treace Medical Concepts (TMCI) with a price target of $4.00. Newitter, a 5-star analyst, has an average return of 13.0% and a 53.97% success rate, focusing on the Healthcare sector. Additionally, Treace Medical received a Hold rating from TR | OpenAI's Lila Implantra on November 8, while Lake Street maintained a Buy rating on November 7.

    Tip Ranks·
    US
    TMCI
    +9.58%
    Tip Ranks·
    US
    TMCI
    +9.58%

    Treace Medical’s Earnings Call: Growth Amid Challenges

    Treace Medical Concepts, Inc. reported Q3 earnings with notable revenue growth of 11% to $50.2 million and a 49% improvement in adjusted EBITDA, reducing losses to $2.6 million. However, the company revised its 2025 revenue outlook to $211-$213 million, reflecting market challenges and a decline in Lapiplasty volumes. Economic conditions have led to increased deferrals of elective procedures, contributing to a net loss of $16.3 million. Looking ahead, Treace plans to expand its product portfolio and enhance sales capabilities to drive future growth.

    Tip Ranks·
    US
    TMCI
    +9.58%
    Tip Ranks·
    US
    TMCI
    +9.58%

    Treace Medical Concepts Inc reports results for the quarter ended September 30 - Earnings Summary

    Treace Medical Concepts Inc reported a quarterly adjusted loss of 26 cents per share for the quarter ended September 30, slightly better than analysts' expectations of a 28 cents loss. Revenue increased by 11.4% to $50.21 million, surpassing the expected $49.73 million. The company incurred a total loss of $16.29 million this quarter. Analyst ratings are mixed, with an average recommendation of "hold" and a median 12-month price target of $6.43, slightly above the last closing price of $6.23. Shares fell by 7.2% this quarter and 16.3% year-to-date.

    Reuters·
    US
    TMCI
    +9.58%
    Reuters·
    US
    TMCI
    +9.58%

    Treace Medical Concepts (TMCI) Gets a Hold from Stifel Nicolaus

    Treace Medical Concepts (TMCI) received a Hold rating from Stifel Nicolaus, with a price target of $5.00, as reported by analyst Rick Wise. Wise, a 3-star analyst, has a 50.60% success rate. Additionally, BTIG's Ryan Zimmerman also issued a Hold rating, while J.P. Morgan downgraded TMCI to a Sell on the same day.

    Tip Ranks·
    US
    TMCI
    +9.58%
    Tip Ranks·
    US
    TMCI
    +9.58%

    Treace Announces Participation in Two Upcoming Investor Conferences

    PONTE VEDRA, Fla., Nov. 07, 2025 ( GLOBE NEWSWIRE ) -- Treace Medical Concepts, Inc. ( "Treace" or the "Company" ) ( NasdaqGS: TMCI ) , a medical technology company driving a fundamental shift in the surgical treatment of bunions and related midfoot deformities, today announced it will ...

    GlobeNewswire·
    US
    TMCI
    +9.58%
    GlobeNewswire·
    US
    TMCI
    +9.58%